SIC
NKTR icon

SJS Investment Consulting’s Nektar Therapeutics NKTR Stock Holding History

SJS Investment Consulting’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$70 Buy
+1
New +$73 ﹤0.01% 2670
2026
Q1 		– Sell
-58
Closed -$2.45K – 2542
2025
Q4 		$2.45K Buy
+58
New +$3.25K ﹤0.01% 1104
2022
Q1 		– Hold
0
– – – 1132

Other funds holding NKTR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
NNPTE
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne Warszawa, Poland $1.83B AUM 331.52% 1-Year Est. Return
ACL
APEIRON Capital Ltd Hong Kong $156M AUM 183.17% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

SJS Investment Consulting's NKTR Position: Q2 2026 in Review

SJS Investment Consulting opened a new position in Nektar Therapeutics (NKTR) in Q2 2026: 1 share worth $70. The stake represents ﹤0.01% of the portfolio and ranks #2670 among its holdings. This is a return to the name: SJS Investment Consulting previously reported a position in NKTR as recently as Q4 2025.

SJS Investment Consulting first reported a position in NKTR in Q4 2025 and has held it in 2 quarters since. The position peaked at $2.45K in Q4 2025. 82 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • SJS Investment Consulting held 1 share of Nektar Therapeutics worth $70 as of Q2 2026.
  • Nektar Therapeutics was a new SJS Investment Consulting position in Q2 2026.
  • Nektar Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #2670 holding.
  • SJS Investment Consulting first reported a position in Nektar Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • SJS Investment Consulting's Nektar Therapeutics position peaked at $2.45K in Q4 2025.
  • 82 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.